Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Immunovant
company
About
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $200M
- Industries
- Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$200M
Immunovant has raised a total of
$200M
in funding over 2 rounds. Their latest funding was raised on
Aug 2, 2021 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 2, 2021 | Post-IPO Equity | $200M | 1 |
Roivant Sciences
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Immunovant is funded by 1 investors.
Roivant Sciences
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Roivant Sciences
|
Yes | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
